Post-Market BTVA Registry

Inclusion Criteria:

1. Patients will have heterogeneous emphysema, as evidenced by high-resolution computedtomography (HRCT) demonstrating a heterogeneity index > or equal to 1.2 in at leastone segment to be treated

2. Patients must be > or equal to 18 years of age

3. Patients are required to provide informed consent prior to inclusion in the Registry

Exclusion Criteria:

1. FEV1 < 20% predicted

2. DLCO < 20% predicted

3. Inability to walk > 140 meters in 6 minutes (6MWD) following optimized medicalmanagement

4. Unstable COPD (any of the following):

5. > 3 COPD related hospitalizations requiring antibiotics in past 12 months

6. COPD related hospitalization in past 3 months

7. daily use of systemic steroids, i.e. > 5 mg prednisolone

8. Concomitant illnesses or medications that would pose a significant increased riskfor complications following treatment with InterVapor. Examples of particularrelevance include: immune system disorders, immunosuppressant medications ofclinical relevance, bleeding disorders and unstable cardiovascular conditions,history of asthma or alpha-1 antitrypsin deficiency

9. Newly prescribed morphine derivatives within the last 4 weeks

10. Pregnant or breastfeeding

11. Highly diseased lower lobes (tissue to air ratio of <11%)

12. Bacterial infection or symptoms indicative of active infection (i.e., fever,elevated white blood cell count)

13. Presence of single large bulla (defined as > 1/3 volume of lobe) or a paraseptaldistribution of emphysema in the treated lobe

14. Recent respiratory infections or COPD exacerbation in preceding 6 weeks -